Anthracycline-free versus anthracycline-based neoadjuvant therapy in HER2-positive breast cancer: A Propensity score-matched real-world study.
BACKGROUND Anthracycline-free TCHP and anthracycline-based AC-THP are both used as neoadjuvant dual anti-HER2 regimens for HER2-positive breast cancer, but direct comparisons accounting for HER2 immunohistochemistry (IHC) intensity are lacking. Because IHC 3+ tumors respond substantially better to dual blockade, any be...